This startup keeps human skin alive for weeks to train an AI on it
Michael Polansky, Lady Gaga's partner and a former senior figure in tech philanthropy, has spent years building an AI startup that discovers skincare compounds using living skin tissue kept alive outside the body. He is only now talking about it.
Key points
- Michael Polansky, publicly known as Lady Gaga's partner and a former deputy to tech billionaire Sean Parker, has built a stealth AI startup focused on skincare science.
- The company keeps living human skin tissue alive outside the body for several weeks, using it as a testing ground for discovering new skincare compounds.
- An AI model, a type of software trained on large amounts of data to spot patterns, analyses results from those tissue samples.
- The startup went years without public disclosure before Polansky chose to speak about it, first reported by TechCrunch AI.
- No funding figures have been disclosed publicly.
What is this company actually doing?
Polansky's startup runs living skin tissue through a process that keeps it viable for weeks after it leaves the human body, then feeds data from those samples into an AI model to identify ingredients that could work as new skincare treatments.
Think of it like a long-running laboratory experiment, except the experimenter is software. The AI looks at how real skin cells respond to thousands of potential compounds far faster than a human scientist could test them one by one.
That speed matters. Traditional skincare research can take years to move from a promising ingredient to a product you can buy. Cutting that timeline has real commercial value.
Who is Michael Polansky?
Polansky is not a household name in tech, but he ran major initiatives inside the Parker Foundation, the philanthropic vehicle of Napster co-founder and early Facebook president Sean Parker. He is also widely recognised as the long-term partner of singer Lady Gaga.
He kept this venture quiet for years. That kind of stealth is common in biotech, where companies race to protect intellectual property before going public with what they have built.
What does this mean for ordinary shoppers?
Nothing immediate lands on shelves tomorrow. But the approach points toward a real shift in how cosmetics companies find new ingredients. If AI-driven tissue testing shortens the research cycle, products built on better science could reach consumers sooner and at lower development cost.
It also raises fair questions about where the skin tissue comes from and how donors consent to its use. Those are details the company has not addressed publicly yet, and they matter.
Survivor bias is worth flagging here too. Plenty of biotech AI startups announce bold science and never ship a product. Polansky's company has operated quietly, which is at least a sign it was not built purely for headlines.
What happens next?
No funding round or product launch has been announced. Going public with the story is likely a first step toward raising outside investment or finding commercial partners in the beauty and pharmaceutical industries.
Watch for a funding announcement. That will be the first hard number that tells us how seriously the market is taking the science.
One honest takeaway: If you work in skincare formulation, cosmetics buying, or dermatology research, AI-assisted compound discovery is no longer theoretical. Start asking your suppliers what their testing pipelines look like.
